Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR

Receptors for Dopamine and Somatostatin: Formation of Hetero-Oligomers with Enhanced Functional Activity

Magalie Rocheville, Daniela C. Lange, Ujendra Kumar et al. · Science · 2000 · 876 citations

Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease

R Zanettini, Angelo Antonini, Gemma Gatto et al. · New England Journal of Medicine · 2007 · 874 citations · Full text

Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist

Aart Jan van der Lely, R. Kent Hutson, Peter Trainer et al. · The Lancet · 2001 · 637 citations

Growth Hormone, Human Growth, Long-term Treatment +4

The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘cure’

P. Nomikos, Michael Buchfelder, Rudolf Fahlbusch · European Journal of Endocrinology · 2005 · 500 citations

Cabergoline in the Treatment of Acromegaly: A Study in 64 Patients

Roger Abs, Johan Verhelst, Dominique Maiter et al. · The Journal of Clinical Endocrinology & Metabolism · 1998 · 363 citations · Full text